Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso® in Patients with Non-Small Cell Lung Cancer

CHENGDU, China and SEATTLE and LONDON, May 13, 2022 /PRNewswire/ — BAILI-BIOPHARMACEUTICAL CO., LTD. (“Baili”) and its wholly owned subsidiary, SystImmune, Inc (“SystImmune”), announced today that it has entered into a clinical trial collaboration and supply agreement with AstraZeneca…

Click here to view original post